CERo Therapeutics Doses Seventh Patient in Phase 1 Trial
The seventh patient has been dosed in the second cohort of CER-1236's Phase 1 trial.
Story updates
01:17:03 PM UTC
SquawkNews
CERo has dosed the seventh patient in its Phase 1 CER-1236 trial, including the fourth patient in the second cohort. The prior three second-cohort patients had no dose-limiting toxicities during the assessment period; monitoring is ongoing.Material DetailsContext by AI AnalystThis is an early-stage…